Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q…
News
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr
Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q…
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern Time SAN DIEGO, July…
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
Webinar Being Held on August 8, 2023 at 12:00 p.m. Eastern Time SAN DIEGO, July…
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Cullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”)…
Cullinan Oncology to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”)…
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
BioNTech Completes Acquisition of InstaDeep
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design…
BioNTech Completes Acquisition of InstaDeep
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design…
Recce Pharmaceuticals to Present at the 2023 Military Health System Research Symposium (MHSRS)
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
Recce Pharmaceuticals to Present at the 2023 Military Health System Research Symposium (MHSRS)
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing…
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing…
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva”…
Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August
CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva”…